<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20532" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dimercaprol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dawn</surname>
            <given-names>Lauren</given-names>
          </name>
          <aff>LSU-HSC Shreveport</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Whited</surname>
            <given-names>Lacey</given-names>
          </name>
          <aff>LSUHSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lauren Dawn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lacey Whited declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20532.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Dimercaprol is a medication used to treat toxic exposure to arsenic, mercury, gold, and lead. It is in the chelating class of drugs. This activity outlines and reviews the indications, actions, and contraindications for dimercaprol as a valuable agent in treating arsenic, mercury, gold, and lead toxicity. This activity will highlight the mechanism of action, adverse event profile, and other key factors such as dosing, pharmacokinetics, and monitoring pertinent for healthcare team members in the treatment of patients with heavy metal toxicity and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the indications for dimercaprol.</p></list-item><list-item><p>Identify the mechanism of action of dimercaprol.</p></list-item><list-item><p>Describe the adverse effects of dimercaprol.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance dimercaprol and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20532&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20532">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20532.s2" sec-type="Indications">
        <title>Indications</title>
        <p>In 1940, Sir Rudolph Albert Peters&#x02019; group at the University of Oxford, UK, developed dimercaprol (2,3-dimercapto-1-propanol), also known as British anti-Lewisite (BAL), as an antidote to lewisite, the arsenical chemical weapon used during World War II.<xref ref-type="bibr" rid="article-20532.r1">[1]</xref>&#x000a0;Shortly after its development, dimercaprol was also found to be just as effective for other metals such as mercury, gold, lead, and copper.</p>
        <p>Prior to the development of penicillamine and trientine, dimercaprol was the only therapy for copper excretion in Wilson disease. However, some have suggested that there may still be a need for short-term therapy with dimercaprol in patients with a severe neurological disability because it can penetrate the blood-brain barrier.<xref ref-type="bibr" rid="article-20532.r2">[2]</xref></p>
        <p>Currently, dimercaprol is FDA-approved in the treatment of the following:</p>
        <p>
<bold>Arsenic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Toxic exposure to arsenic and markedly elevated urine arsenic concentrations</p>
          </list-item>
          <list-item>
            <p>Arsenic-related skin injuries (e.g., lewisite)<xref ref-type="bibr" rid="article-20532.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Mercury</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute or chronic elemental mercury exposure with a whole blood mercury concentration or 24-hour urine concentration of &#x02265; 100 mcg/L</p>
          </list-item>
          <list-item>
            <p>Acute inorganic mercury poisoning when whole blood mercury concentration or 24-hour urine concentration is greater than or equal to 100 mcg/L</p>
          </list-item>
        </list>
        <p>
<bold>Gold</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gold-induced thrombocytopenia: Injections with gold salts have been used in the treatment of rheumatoid arthritis.</p>
          </list-item>
        </list>
        <p>
<bold>Lead</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe symptomatic lead poisoning, lead encephalopathy, or&#x000a0;a whole blood lead concentration above 100 mcg/dL in adults and above 70 mcg/dL in children</p>
          </list-item>
          <list-item>
            <p>To prevent redistribution of lead to the brain, Dimercaprol is given before calcium disodium edetate, another chelating agent.<xref ref-type="bibr" rid="article-20532.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>The water-soluble derivative of dimercaprol, 2,3-dimercaptosuccinic acid (DMSA), is FDA-approved for treating toxic exposure to lead in children when whole blood concentrations are above 45 mcg/dL, although there have been case reports of its use in adult patients.<xref ref-type="bibr" rid="article-20532.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>The more modern chelating agent DMSA has replaced dimercaprol due to its broader therapeutic index and fewer adverse effects. However, outside the United States, another water-soluble derivative of dimercaprol, 2,3-dimercapto-1-propane sulfonic acid (DMPS), is often used instead.</p>
      </sec>
      <sec id="article-20532.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>A major protein modified by heavy metal toxicity is lipoic acid, which is necessary for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, leading to the disruption of the citric acid cycle and the accumulation of pyruvic acid.<xref ref-type="bibr" rid="article-20532.r6">[6]</xref></p>
        <p>Dimercaprol is a dithiol that acts by forming a stable five-membered ring between its sulfhydryl groups and certain heavy metals, thereby neutralizing its toxicity and promoting its elimination.</p>
        <p>Dimercaprol is more efficacious when given soon after the metal exposure because it is better at preventing enzyme inhibition than reactivating enzyme function.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>
<bold>Absorption</bold>
</p>
        <p>Dimercaprol undergoes rapid absorption after deep intramuscular injection. Peak plasma concentration occurs within 30 to 60 minutes.</p>
        <p>
<bold>Distribution</bold>
</p>
        <p>Dimercaprol is highly lipophilic and readily crosses into the intracellular space. As a result, it gets distributed in all tissues, and it is most concentrated in the liver, kidneys, brain, and small intestines.</p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>Dimercaprol that is not complexed with metal undergoes hepatic metabolism via glucuronidation and gets converted into inactive metabolites.</p>
        <p>
<bold>Excretion</bold>
</p>
        <p>Dimercaprol has a short half-life and is excreted as an inactive metabolite or complexed with metal. The kidneys mainly eliminate dimercaprol, but a small amount gets eliminated in bile. Dissociation of the bond between the metal and sulfhydryl group can occur in the acidic tubular urine and cause the redistribution of metal into renal tissue. Therefore, it is crucial to maintain a dimercaprol concentration in the plasma that favors the continuous formation and excretion of the stable dimercaprol-metal complex.</p>
      </sec>
      <sec id="article-20532.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Dimercaprol is administered by a deep intramuscular injection (IM) in the top lateral quadrant of the buttocks. Multiple doses must be given for several days to weeks, and the injection sites alternate between the right and left buttocks, approximately two inches below the previous ones.&#x000a0;Maintaining an alkaline urine pH is also recommended to protect renal function. Blood and urine concentrations, alleviation of symptoms, and dimercaprol toxicity are the major factors when determining management with dimercaprol.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p><bold>Arsenic or gold poisoning (mild):</bold>&#x000a0;Deep IM: 2.5 mg/kg every 4 hours for 6 doses, then every 6 hours for 4 doses, then every 8 hours for 3 doses, then every 12 hours for 2 doses, followed by once daily for 10 days.</p>
        <p><bold>Arsenic or gold poisoning (moderate):</bold>&#x000a0;Deep IM: 2.5 to 3.5 mg/kg every 4 hours for 6 doses, then every 6 hours for 4 doses, then every 8 hours for 3 doses, then every 12 hours for 2 doses, followed by once daily for 10 days.</p>
        <p><bold>Arsenic or gold poisoning (severe):</bold>&#x000a0;Deep IM: 3.5 to 5 mg/kg every 4 hours for 6 doses, then every 6 hours for 4 doses, then every 8 hours for 3 doses, then every 12 hours for 2 doses, followed by once daily for 10 days&#x000a0;<xref ref-type="bibr" rid="article-20532.r7">[7]</xref></p>
        <p><bold>Elemental and inorganic mercury poisoning (moderate to severe):</bold>&#x000a0;Deep IM: 5 mg/kg every 4 hours for 1 to 2 days, then 2.5 mg/kg 1 to 2 times/day for 10 days</p>
        <p><bold>Lead poisoning:</bold>&#x000a0;Deep IM: 4 mg/kg every 4 hours for 3 days and 2.5 mg/kg for 1 to 4 days; dimercaprol is given in combination with calcium disodium edetate; dimercaprol should be administered first, and calcium disodium edetate should be administered at&#x000a0;a different site than dimercaprol</p>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <p><bold>Arsenic or gold poisoning (mild):</bold>&#x000a0;Deep IM: 2.5 mg/kg every 4 hours for 6 doses, then every 6 hours for 4 doses, then every 8 hours for 3 doses, then every 12 hours for 2 doses, followed by once daily for 10 days.</p>
        <p><bold>Arsenic or gold poisoning (moderate):</bold><bold>&#x000a0;</bold>Deep IM: 2.5 to 3.5 mg/kg every 4 hours for 6 doses, then every 6 hours for 4 doses, then every 8 hours for 3 doses, then every 12 hours for 2 doses, followed by once daily for 10 days.</p>
        <p><bold>Arsenic or gold poisoning (severe):</bold>&#x000a0;Deep IM: 3.5 to 5 mg/kg every 4 hours for 6 doses, then every 6 hours for 4 doses, then every 8 hours for 3 doses, then every 12 hours for 2 doses, followed by once daily for 10 days.</p>
        <p><bold>Elemental and inorganic mercury poisoning (moderate to severe): </bold>Deep IM: 5 mg/kg every 4 hours for 1 to 2 days, then 2.5 mg/kg 1 to 2 times/day for 10 days</p>
        <p><bold>Lead poisoning:</bold> 4 mg/kg every 4 hours for 3 days and 2.5 mg/kg for 1 to 4 days; dimercaprol is given in combination with calcium disodium edetate; dimercaprol should be administered first, and calcium disodium edetate should be administered at&#x000a0;a different site than dimercaprol.</p>
        <p>
<bold>Renal Impairment&#x000a0;</bold>
</p>
        <p>No adjustments are needed in the presence of&#x000a0;renal disease, but if acute kidney injury develops during treatment, discontinuation of dimercaprol&#x000a0;is recommended.</p>
        <p>
<bold>Hepatic Impairment</bold>
</p>
        <p>Except due to arsenic toxicity, dimercaprol is contraindicated in hepatic insufficiency.</p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Iron supplements and preparations should be avoided with dimercaprol therapy. Dimercaprol potentially increases the nephrotoxic effects of iron salts.</p>
      </sec>
      <sec id="article-20532.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>There are many adverse effects associated with the chelating agent dimercaprol. Signs and symptoms appear to depend on dosage and the time between each dose with hypertension, tachycardia, nausea, and vomiting most frequently noted.</p>
        <p>Other adverse effects observed are headaches, weakness, abdominal pain, burning sensations in the eyes, nose, mouth, blepharospasm, lacrimation, salivation, rhinorrhea, sweating, flushing, restlessness, anxiety, chest tightness, and generalized myalgia in children and adults. Fever occurs in 30% of children.<xref ref-type="bibr" rid="article-20532.r8">[8]</xref><xref ref-type="bibr" rid="article-20532.r1">[1]</xref>&#x000a0;The administration of dimercaprol is also very painful due to the repeated deep intramuscular injections, and in many cases, patients have developed hematomas at the injection site.<xref ref-type="bibr" rid="article-20532.r9">[9]</xref></p>
      </sec>
      <sec id="article-20532.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Dimercaprol is formulated in peanut oil and is contraindicated in any patient with peanut allergies. Peanut oil is lipid-soluble and was inexpensive when dimercaprol came on the market. There is currently no other FDA-approved solvent for dimercaprol.</p>
        <p>Dimercaprol is considered contraindicated in chronic inorganic and organic mercury exposure. Berlin and Rylander reported chronic exposure to organic mercury with dimercaprol therapy doubles the amount of mercury deposited in the brain compared to animals only receiving mercury. Therefore, DMSA is the optimal chelating agent in these cases.<xref ref-type="bibr" rid="article-20532.r10">[10]</xref><xref ref-type="bibr" rid="article-20532.r11">[11]</xref></p>
        <p>Dimercaprol is contraindicated in hepatic insufficiency. In animal studies by Cameron et al., toxic symptoms and death were observed in rabbits and mice with hepatic damage treated with dimercaprol. These results occurred with doses well below the lethal dose in healthy animals.<xref ref-type="bibr" rid="article-20532.r12">[12]</xref>&#x000a0;In patients with glucose 6-phosphate dehydrogenase deficiency, treatment with dimercaprol requires extreme caution due to an increased risk of hemolytic anemia.</p>
      </sec>
      <sec id="article-20532.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The narrow therapeutic window of dimercaprol appears to be time and dose-dependent. Case reports have shown that doses above 3 mg/kg dimercaprol given every 4 hours or less will cause adverse effects in up to two-thirds of patients. Thus, toxicity in most patients can be avoided by a dose of less than 3 mg/kg and allowing at least 4 hours between each dose.<xref ref-type="bibr" rid="article-20532.r13">[13]</xref><xref ref-type="bibr" rid="article-20532.r14">[14]</xref>&#x000a0;Several adverse effects have occurred with dimercaprol, such as nausea, vomiting, abdominal pain, tachycardia, hypertension, headache, burning sensation in the eyes, nose, and mouth, diaphoresis, lacrimation, blepharospasm, rhinorrhea, and anxiety.&#x000a0;</p>
        <p>While the precise mechanism of toxicity is unknown, some have speculated that it may result from removing metal from enzymes disrupting their normal function, while others have postulated toxicity occurs when there is excess dimercaprol that remains unbound to the metal in the body.<xref ref-type="bibr" rid="article-20532.r15">[15]</xref><xref ref-type="bibr" rid="article-20532.r7">[7]</xref>&#x000a0;In all the human volunteers and case reports of dimercaprol toxicity, signs and symptoms resolved within 1 to 4 hours after the injections, and no signs of cumulative toxicity occurred with repeated injections.<xref ref-type="bibr" rid="article-20532.r16">[16]</xref></p>
      </sec>
      <sec id="article-20532.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There are no antidotes available for dimercaprol. Therefore, if toxicity presents with dimercaprol, cessation of therapy is recommended until the resolution of symptoms. Clinical judgment should be used to determine whether to continue, taper off, or discontinue treatment with dimercaprol.</p>
      </sec>
      <sec id="article-20532.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Heavy metal toxicity is a serious condition that can cause high morbidity and mortality, and prompt management with chelation therapy is crucial in severe cases. [Level 5] All interprofessional healthcare team members must be aware of the signs and symptoms of acute heavy metal toxicity and the appropriate steps necessary. In suspected or known exposures, the clinician and pharmacist should consult the regional poison control center, and chelating agents such as dimercaprol should be obtained from the facility if not already in supply.</p>
        <p>Emergency department physicians, nurses, pharmacists, laboratory technologists, and physicians of other specialties must all work together when coordinating a plan of care for the patient. Whole blood concentrations and 24-hour urine concentrations of arsenic, mercury, gold, or lead are necessary for determining the level of toxicity, the dose of the chelating agent, and monitoring therapy. Other labs to assess hepatic and renal function are also important when managing chelation therapy. [Level 4]</p>
        <p>Throughout their hospital course, the patient should be monitored for signs and symptoms of worsening heavy metal toxicity, adverse effects of dimercaprol or other chelating agents, and the alleviation of symptoms. Nursing can help the team assess the effectiveness of treatment, administer dimercaprol, and report any concerns to the treating clinician. A social worker may also be consulted to assist the patient and family members when dealing with occupational or home exposures. These are only examples of how working as an interprofessional team can significantly impact the morbidity and mortality of heavy metal toxicity&#x000a0;and the appropriate use of dimercaprol. [Level 5]</p>
      </sec>
      <sec id="article-20532.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20532&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20532">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20532/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20532">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20532.s11">
        <title>References</title>
        <ref id="article-20532.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>PETERS</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>STOCKEN</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>THOMPSON</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>British anti-lewisite (BAL).</article-title>
            <source>Nature</source>
            <year>1945</year>
            <volume>156</volume>
            <fpage>616</fpage>
            <page-range>616-9</page-range>
            <pub-id pub-id-type="pmid">21006485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheinberg</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Sternlieb</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Treatment of the neurologic manifestations of Wilson's disease.</article-title>
            <source>Arch Neurol</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>339</fpage>
            <page-range>339-40</page-range>
            <pub-id pub-id-type="pmid">7710368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mouret</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wartelle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Emorine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nguon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cl&#x000e9;ry-Barraud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dorandeu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boudry</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Topical efficacy of dimercapto-chelating agents against lewisite-induced skin lesions in SKH-1 hairless mice.</article-title>
            <source>Toxicol Appl Pharmacol</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>272</volume>
            <issue>2</issue>
            <fpage>291</fpage>
            <page-range>291-8</page-range>
            <pub-id pub-id-type="pmid">23806213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chisolm</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood.</article-title>
            <source>J Pediatr</source>
            <year>1968</year>
            <month>Jul</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-38</page-range>
            <pub-id pub-id-type="pmid">4969284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Management of Lead Encephalopathy with DMSA After Exposure to Lead-Contaminated Moonshine.</article-title>
            <source>J Med Toxicol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>464</fpage>
            <page-range>464-7</page-range>
            <pub-id pub-id-type="pmid">26245877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alessio</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The use of chelating agents in occupational lead poisoning.</article-title>
            <source>Occup Med (Lond)</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-8</page-range>
            <pub-id pub-id-type="pmid">8672793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>WOODY</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>KOMETANI</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>BAL in the treatment of arsenic ingestion of children.</article-title>
            <source>Pediatrics</source>
            <year>1948</year>
            <month>Mar</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>372</fpage>
            <page-range>372-8</page-range>
            <pub-id pub-id-type="pmid">18908858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>GOLDSTEIN</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>RANDALL</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>GROSS</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>ROSEVEAR</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>McGUCKIN</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Wilson's disease (hepatolenticular degeneration) with DL-penicillamine.</article-title>
            <source>Neurology</source>
            <year>1962</year>
            <month>Apr</month>
            <volume>12</volume>
            <fpage>231</fpage>
            <page-range>231-44</page-range>
            <pub-id pub-id-type="pmid">13899920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kosnett</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The role of chelation in the treatment of arsenic and mercury poisoning.</article-title>
            <source>J Med Toxicol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>347</fpage>
            <page-range>347-54</page-range>
            <pub-id pub-id-type="pmid">24178900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>BERLIN</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>RYLANDER</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>INCREASED BRAIN UPTAKE OF MERCURY INDUCED BY 2,3-DIMERCAPTOPROPANOL (BAL) IN MICE EXPOSED TO PHENYLMERCURIC ACETATE.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1964</year>
            <month>Nov</month>
            <volume>146</volume>
            <fpage>236</fpage>
            <page-range>236-40</page-range>
            <pub-id pub-id-type="pmid">14236935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersen</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Principles and recent developments in chelation treatment of metal intoxication.</article-title>
            <source>Chem Rev</source>
            <year>1999</year>
            <month>Sep</month>
            <day>08</day>
            <volume>99</volume>
            <issue>9</issue>
            <fpage>2683</fpage>
            <page-range>2683-710</page-range>
            <pub-id pub-id-type="pmid">11749497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cameron</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Trenwith</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>The possibility of toxic effects from 2:3-dimercaptopropanol in conditions of impaired renal or hepatic function.</article-title>
            <source>Br J Pharmacol Chemother</source>
            <year>1947</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-64</page-range>
            <pub-id pub-id-type="pmid">19108105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bunch</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Gold overdose treated with BAL.</article-title>
            <source>Arthritis Rheum</source>
            <year>1976</year>
            <season>Jan-Feb</season>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>123</fpage>
            <page-range>123-5</page-range>
            <pub-id pub-id-type="pmid">1252266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ZAROWITZ</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>NELSON</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A case of acute BAL toxicity during treatment of gold glossitis.</article-title>
            <source>N Y State J Med</source>
            <year>1949</year>
            <month>Aug</month>
            <day>15</day>
            <volume>49</volume>
            <issue>16</issue>
            <fpage>1965</fpage>
            <pub-id pub-id-type="pmid">18136352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webb</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Van Heyningen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The action of British anti-lewisite (BAL) on enzyme systems.</article-title>
            <source>Biochem J</source>
            <year>1947</year>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-8</page-range>
            <pub-id pub-id-type="pmid">16748122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20532.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sulzberger</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Baer</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Kanof</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). III. STUDIES ON THE TOXICITY OF BAL ON PERCUTANEOUS AND PARENTERAL ADMINISTRATION.</article-title>
            <source>J Clin Invest</source>
            <year>1946</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>474</fpage>
            <page-range>474-9</page-range>
            <pub-id pub-id-type="pmid">16695340</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
